Inna Kovalevska, Olena Ruban, Vadim Khanin


Aim. The purpose of our study was to develop a method for simultaneous quantitation of voglibose and quercetin in a solid dosage form.

Materials and methods. The objects of the study were voglibose, quercetin, tablets containing voglibose - 0.2 mg and quercetin 100 mg. Measurements were carried out by high-performance liquid chromatography (HPLC) according to SPHU, supp. 1, 2.2.29, N, using the following equipment: a mass-selective detector Agilent 6530 Q-TOF was used as the detecting system.

Results. According to the developed method, the quantitative determination of voglibose and quercetin in the tablets of hypoglycaemic action was investigated. The following results were obtained: the content of C 10 H 21 NO 7 (voglibose) in one dosage unit of the test drug was 0.2 mg; and the content of C 15 H 10 O 7 (quercetin) -0.105 g, which suggests the validability of the proposed method for quantitation of the active substances in tablets for the prevention and treatment of type II diabetes mellitus.

Conclusions. In the course of the study, a method was developed for determination of voglibose and quercetin in a hypoglycaemic action preparation using high-performance liquid chromatography (HPLC) with a gradient mode of elution. It has been established that the chosen chromatographic conditions allow quantitative determination of the active pharmaceutical ingredients studied in a solid dosage form with a tolerance of ±5 %. Validation of the developed methodology has been conducted and its suitability for the simultaneous quantification of quercetin and voglibose in tablets has been demonstrated. The reproducibility of this method has been proved.


voglibose; quercetin; high-performance liquid chromatography; diabetes mellitus; combination therapy

Full Text:



Whiting, D. R., Guariguata, L., Weil, C., Shaw, J. (2011). IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Research and Clinical Practice, 94 (3), 311–321. doi:

Hollander, P. (2007). Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes. Diabetes Spectrum, 20 (3), 159–165. doi:

Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R. et. al. (2017). Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. Frontiers in Endocrinology, 8. doi:

Neborachko, M., Pkhakadze, A., Vlasenko, I. (2018). Current trends of digital solutions for diabetes management. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 12 (4). doi:

Germanyuk, Т. А., Іvko, Т. І. (2014). Rational choice of monotherapy for the treatment of type 2 diabetes mellitus based on the pharmacoeconomical analysis. ScienceRise, (5 (4 (5)), 69–72. doi:

Nyenwe, E. A., Jerkins, T. W., Umpierrez, G. E., Kitabchi, A. E. (2011). Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism, 60 (1), 1–23. doi:

Singh Baghel, S., Shrivastava, N., Singh Baghel, R., Agrawal, P., Rajput, S. (2012). A review of quercetin: antioxidant and anticancer properties. World journal of pharmacy and pharmaceutical sciences, 1 (1), 146–160.

Butler, M. S., Robertson, A. A. B., Cooper, M. A. (2014). Natural product and natural product derived drugs in clinical trials. Natural Product Reports, 31 (11), 1612–1661. doi:

Boots, A. W., Haenen, G. R. M. M., Bast, A. (2008). Health effects of quercetin: From antioxidant to nutraceutical. European Journal of Pharmacology, 585 (2-3), 325–337. doi:

Chikitkina, O. M., Kononenko, N. M. (2015). Antioxidant properties of a new combined agent glikverin in terms of chemically induced absolute insulin deficiency. Topical issues of new drugs development. Kharkiv: NUPh, 646.

Kovalevska, I., Ruban, O. (2018). Development of the methodological approach of obtaining preparations based on solid dispersions. ScienceRise: Pharmaceutical Science, 4 (14), 4–8. doi:

Dabhi, A. S., Bhatt, N. R., Shah, M. J. (2013). Voglibose: an alpha glucosidase inhibitor. Journal of Clinical and Diagnostic Research, 7 (12), 3023–3027. doi:

Kovalevska, I. V., Ruban, O. A. (2018). Modern direction of increasing bioavailability of drugs. Young scientists’ view of modern science. Morrisville: Lulu Press, 89–94.

Kaku, K. (2014). Efficacy of voglibose in type 2 diabetes. Expert Opinion on Pharmacotherapy, 15 (8), 1181–1190. doi:

Dabhi, A. S., Bhatt, N. R., Shah, M. J. (2013). Voglibose: an alpha glucosidase inhibitor. Journal of Clinical and Diagnostic Research, 7 (12), 3023–3027.

State Pharmacopoeia of Ukraine. Vol. 2 (2014). Kharkiv: State Enterprise " Ukrainian Scientific Pharmacopoeial Center for Quality of Medicinal Products&quot, 1125.

Shabir, G. A. (2003). Validation of high-performance liquid chromatography methods for pharmaceutical analysis: Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization. Journal of Chromatography A, 987 (1-2), 57–66. doi:

Batrawi, N., Wahdan, S., Abualhasan, M. (2017). Analytical Method Validation of High-Performance Liquid Chromatography and Stability-Indicating Study of Medroxyprogesterone Acetate Intravaginal Sponges. Analytical Chemistry Insights, 12. doi:

Chikitkina, O. M., Kononenko, N. M., Kovalevsky, I. V. (2015). Experimental substantiation of the dose of voligibose in the new antidiabetic agent gliverine. Ukrainian biopharmaceutical journal, 2, 38–43.

Kovalevskaya, I. V., Kononenko, N. N., Chikitkina, O. M., Chikitkina, V. V. (2014). Experimental substantiation of dose selection and carrier for quercetin substance in the new antidiabetic agent Glikverin. Pharmacology and Drug Toxicology, 3, 57–63.



  • There are currently no refbacks.

Copyright (c) 2019 Inna Kovalevska, Olena Ruban, Vadim Khanin

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2504-5679 (Online), ISSN 2504-5660 (Print)